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Natural killer cell function in hemodialysis patients: Effect of the
dialysis membrane. Natural killer (NK) cells are specific peripheral
blood lymphocytes which are involved in the lysis of malignant and
virally transformed cells. In a prospective study of eight hemodialysis
patients, we investigated the effects of recurrent exposure to the
cuprophane (CU) membrane on the number and functional ability of
NK cells, against both their classical in vitro target, K562 cell line, as
well as the f32m/HLA negative cells that emerge during dialysis with CU
membrane. The percent of NK cells, defined by the CD56 epitope,
increased from 27.7 7.9% of cells at baseline to 59.2 12,0% after
two weeks of dialysis with new CU membrane (P < 0.01). The ability of
these cells to lyse K562 cells decreased from 28.7 16.5% at baseline
to 12.5 6.2% (P < 0.001) after two weeks of dialysis with CU
membrane, while their cytotoxicity against f32m negative cells increased
during the same period from 32.5 12.4% to 61.3 23.7% (P < 0.001).
These results are consistent with the observation that the cytolytic
ability of NK cells is inversely related to target cell expression of HLA
antigens and /32m expression on cell surfaces. In addition, the results of
these studies confirm in Vitro observations of the decrease in cytolytic
activity of the NK cells when exposed to the CU membrane, and may
explain the emergence of these /32m/HLA negative cells during dialysis
with CU membrane. It is possible that these observations may also have
a clinical relevance to the immune defects and increased incidence of
malignancy in uremia.
Natural killer (NK) cells comprise 10 to 15% of peripheral
blood lymphocytes and are defined functionally by their ability
to spontaneously lyse autologous and allogeneic target cells
without deliberate prior sensitization and without restriction by
major histocompatibility (MHC) alloantigens [1]. In vivo, these
cells are important in the destruction of autologous tumor cells
and resistance to viral infections and play a role in graft versus
host disease [1—4].
Resting NK cells have pre-formed cytolytic granules that can
be discharged immediately after exposure to specific target cells
[5]. Susceptibility to NK cell killing appears to be inversely
related to target cell expression of HLA antigens (especially
class I, but also class II) and to unassociated /32 microglobulin
expression on cell surfaces [6-42].
In general, NK cells are not phagocytic and their operational
definition is based on their cytolytic activity. In patients with
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severe immunodeficiency state, such as patients with AIDS,
NK cells are at very low levels, while in patients with malig-
nancy, NK cell function is significantly reduced [13]. Although
no single surface antigen unambiguously identifies all human
NK cells, CD56 (NKH-l, Leu-19) is expressed by more than
95% of these cells [1, 14—17].
In vitro, NK cell function has been assessed in co-culture
cytolytic assay of K562 cultured cell line, which have normal
Beta 2-microglobulin (/32m) expression but low or absent class I
antigen expression [18]. Optimal stimulation of in vitro cytolytic
activity requires the presence of interleukin-2 (IL-2) or interfer-
on-y (IF-y) [19—22].
Using flow cytometric techniques, we recently reported on
the emergence of peripheral blood mononuclear cells (PBMNC)
with reduced J32m and HLA expression following chronic
dialysis with new cuprophane membranes. The proportion of
these cells with reduced or absent J32mIHLA expression in-
creased with duration of dialysis and reached approximately
25% of PBMNC after two weeks of dialysis with new Cu-
prophane membranes. This proportion gradually decreased
toward baseline of approximately 5% with institution of dialysis
with biocompatible membrane [23].
With this observation as a background, we investigated in a
prospective study the behavior of NK cells, both against its
classical target K562 cells, and against the isolated /32m/HLA
negative cells that emerged during dialysis with cuprophane
membrane.
Previous work on NK cell function in hemodialysis patients
has been contradictory; while some studies reported NK cell
function in dialysis patients to be normal [24], others found it to
be decreased [25]. More recently, Raij reported a significant
deterioration of NK cell function when exposed to the cu-
prophane membrane in vitro [26, 27].
Methods
Materials
Patient population. Eight chronic hemodialysis patients, clin-
ically stable and without hospitalization for the previous six
months were chosen for the study from the Nashville VA
Dialysis Center. None of the patients were diabetic. All were
free of infectious complications during the period of this study,
and none had evidence for an active inflammatory or autoim-
mune disease process, HIV, hepatitis or malignancy. None of
the patients were on steroid or immunosuppressive therapy.
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None had received a transfusion in the last year [28]. All
patients were on calcitriol [29]. Seven of the eight patients were
on 0.25 g daily dose of oral calcitriol while the eighth patient
was on 0.50 ,.g daily. Average PTH concentration (intact
molecule assay, normal is 10 to 55 pg/mI) in these patients was
286 287 pg/mI (mean SD). All patients were also on
erythropoietin (EPO) therapy with an average dose of 4,200
700 units i.v. every dialysis treatment. The average hematocrit
was 29.6 3.4%. The mean age of the patient was 59 14 years
(range 40 to 68 years) and there were seven males and one
female, reflecting the dialysis population of the VA Hospital.
During the period of the study, there were no changes in the
dialysis prescription, except for a change of dialyzer membrane
for the study. All dialyses were performed using bicarbonate as
the base in the dialysate [30]. The composition of the dialysate
was: sodium 140 mEq/liter, potassium 2 mEq/liter, bicarbonate
39 mEq/liter, calcium 2.7 mEq/liter, chloride 107 mEq/liter,
magnesium 1.0 mEqlliter, acetate 4 mEq/liter and dextrose 150
mg/dl. Ten laboratory and dialysis personnel were chosen as
controls. The mean age of the controls was 36 14 (range 22 to
59). None had any known disease and none were taking any
medications.
Methods
Study design. The design of the study was a prospective,
crossover design. After informed consent, patients agreeing to
participate in the study were placed on a low flux, biocompat-
ible polymethylmethacrylate (PMMA) membrane (B2- 150,
Toray, Tokyo, Japan) for a period of two months. This was
designed to reduce the number of 132m/HLA negative cells to a
baseline level as shown previously [23]. The patients were then
placed on new cuprophane membranes (CD15.l1, Baxter
Healthcare, McGraw Park, Illinois, USA) for two weeks (six
consecutive dialyses). No reuse was performed during the
study, including the baseline period.
Blood was drawn post-dialysis at the end of the last dialysis
with the PMMA membrane, which was considered as baseline.
Blood was also drawn postdialysis at the end of the first dialysis
with cuprophane, at the end of the first week (that is, after three
dialyses) and at the end of two weeks (that is, six dialyses) with
new cuprophane membranes.
Sample preparation
IL-2 activated cell cultures. Forty milliliters of blood were
mixed with equal amounts of Hank's balanced salt solution
(HBSS; Gibco, Grand Island, New York, USA) and carefully
layered over Histopaque (Sigma Chemical, St. Louis, Missouri,
USA) media allowing gradient density centrifugation. The
mononuclear cell layer was collected and washed twice with
HBSS, and the red blood cells were lysed by hypotonic lysis x
2. The PBMNC cell layer was resuspended in RPM! 1640
supplemented with 2 mivi L-glutamine (Gibco), 100 p/mI peni-
cillin G, 10 pg/ml streptomycin (Sigma) and 10% de-comple-
mented, sterile-filtered certified fetal calf-serum (FCS, Gibco).
Cell concentration was maintained at 106 cells/ml. All cultures
were incubated with recombinant interleukin-2 (IL-2), at a final
concentration of 50 j.tJml (Genzyme, Massachusetts, USA) in a
37°C, 5% CO2 incubator for 18 hours, the time of maximal NK
cell mediated cytotoxicity [15, 21, 31, 32]. In preliminary
experiments, the percent increase in K562 cytolysis by addition
of IL-2 was the same in normal controls and dialysis patients at
baseline. As indicated earlier, at baseline these patients were
dialyzed with the PMMA membranes and bicarbonate dialy-
sate.
Cytofluorometric assay. A total of 2.5 to 5 x iO cells were
incubated with 0.5 pg monoclonal anti-/32m antibody from a
mouse hybridoma (a gift from Dr. M. Hass, Abbott Laborato-
ries, Chicago, Illinois, USA) for 30 minutes at 4°C; excess
antibody was washed and cells resuspended in 500 pl PBS,
0.01% sodium azide with the second fluorescent goat antimouse
F(ab)2 fragment (GAM-FITC), added at a concentration of 20
p1/test (Coulter Electronics, Hialeah, Florida, USA) and incu-
bated for 20 minutes at 4°C in the dark. The cells were then
washed twice with 2 ml of PBS, and kept in 500 pl of modified
PBS at 4°C until analysis. Five thousand cells were analyzed
within two hours for green fluorescence on a FACScan (Becton
Dickinson Immunocytometry Systems, Mountainview, Califor-
nia, USA) equipped with a 15 mW Argon laser (excitation
wavelength 488 nm), after gating for lymphocyte population
according to size and granularity. Parallel batches were also
stained with W6/32, an antibody against the monomorphic
determinant of HLA-A, B, C, (Accurate Scientific, New York,
New York, USA) and with anti-CD3 (T cell receptor), anti-
CD16 (B cell); anti-CD56 (Leul9, NKH-l); anti-CD4 and anti-
CD8. Results were expressed as the percentage of these mark-
ers in cells that were either 132m negative or 2m positive
lymphocytes, after isolation (see below). Non-specific fluores-
cence staining with GAM-FITC and irrelevant mouse IgG were
subtracted from each sample.
Enrichment of 2m/HLA negative cells in culture. To isolate
/32m/HLA negative cells from the culture media, we "precipi-
tated" /32m positive cells using magnetic beads and harvested
the 2m negative cells in the supernatant. To do this, we
resuspended 5 x iO cells in 10 ml HBSS and incubated with 5
pl anti-/32m mouse-antibody (same antibody as used in cytoflu-
orimetric assay) for one hour at 4°C, then washed with HBSS x
2. According to the manufacturer's instructions, magnetic
beads covered with goat-antimouse antibody (MAG-GAM,
Advanced Magnetics, Inc., Cambridge, Massachusetts, USA)
were washed x 3, with complete culture media and resus-
pended in HBSS containing 50 pl of irrelevant IgG, to block
non-specific Fc receptors on PBMNC. Cells at a concentration
of 5 x 106/ml and previously incubated with mouse anti-/32m
antibody were mixed with the magnetic beads at a ratio of 100
magnetic beads per cell and resuspended in sterile 25 ml
horizontal flasks (Falcon) for one hour under constant gentle
agitation. After this incubation, flasks were attached to a
Magnetic Separator (Advanced Magnetics Inc.) for ten minutes
with occasional gentle swirling to allow the precipitation of the
magnetic beads and their attached cells to the bottom of the
plates. The supernatants containing the 132m negative cells were
carefully transferred to a new sterile flask. This process of
isolation of 2m negative cells will be referred to subsequently
as "negative separation." These f32m negative cells were resus-
pended in 1 ml RPM! with 2% BSA at 2 x 106 cells/ml. Cell
viability was determined by tryptan blue and a sample (100 p1)
incubated with anti-132m antibody and GAM-FITC, and ana-
lyzed on the flow cytometer as described earlier.
132m positive cells, attached to the magnetic beads, were
resuspended in complete culture media and kept overnight in
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Fig. 1. The efficacy of separation of f32m negative and f32m positive
cells by i,nmunomagnetic beads. In the initial isolate of PBMNC, only
12% of cells have an absent f32m staining, whereas the percent of those
cells increased to 87% in the supernatant after precipitation of the j32m
positive cells by immunomagnetic beads. There were less than 5% of
f32m negative cells in the cells attached to the magnetic beads.
the incubator at 37°C, 5% CO2. Under these conditions, cells
detach from the magnetic beads. f32m positive cells were then
recovered from the beads by applying the magnetic separator
and harvesting the /32m positive cells in the supernatant. (32m
positive cells were counted and resuspended at 2 x 106 cells/mi
in RPM! with 2% BSA. An aliquot (100 d) of this suspension
was incubated with 0.5 1.d anti-(32m antibody and GAM-FITC,
and analyzed on FACScan as described above to ascertain the
purity of the populations in terms of f32m staining. The esti-
mated purity of the separated cell populations was 87 4% I3m
negative cells, and over 98% (32m positive cells (Fig. 1).
Cytotoxicity assays. After separation and ascertainment of
purity of cell preparation, the /37m positive cells were used as
"effector" cells and co-incubated separately with either f32m
negative (autologous "target" cells) or the classical target K562
erythroleukemic cells (courtesy of Dr. Loizzo, University of
Tennessee, Knoxville, Tennessee, USA) [331. For these exper-
iments, 100 d of cell suspension of /32m positive cells (5 X
106/ml) were incubated with the appropriate dilution of 132m
negative cell suspension in triplicates. The dilution of f32m cells
was varied to give an effector to target ratio of 10:1 [10, 31].
Similarly, 100 d of f32m positive cells (5 )< l06/ml) were
incubated in triplicate with K562 cells to give an effector to
target ratio of 50:1.
To determine spontaneous cell lysis (spontaneous cytotoxic-
ity) 100 d of /32m negative cells were incubated in triplicate
with 100 j.tl HBSS-1% BSA. Similarly, to determine total
cytotoxicity, 100 ,td of (32m negative cells were incubated with
100 sl of HBSS plus 1% Triton X-100. Similar controls (that is,
spontaneous and total cytotoxicity) were determined for the
K562 target cells. All incubations studies were carried out in
triplicate, for 18 hours at 37°C and in a 5% CO2 incubator.
Enzyme release assay. Cell lysis was monitored by the
release of cytosolic enzymes in the cytotoxicity assay superna-
tants and measured with a commercial kit according to the
manufacturer instructions (LK-l00 Colorimetric Cytotoxicity
Assay Kit, Proteins International, Rochester Hills, Michigan,
USA). This assay depends on the release of lactic dehydroge-
nase (LDH) from cytosolic to the media upon cell lysis. In brief,
after incubation the cells were subjected to low speed centrif-
ugation and 100 .d of supernatant from each well were trans-
ferred to flat bottom 96-wells plates in triplicates. Empty wells
for blank setting and triplicates of 100 l of RPMI-BSA and
HBSS-Triton for background of spontaneous and total cytotox-
icity enzyme release assays, respectively, were also included in
each plate. One hundred microliters of color reagent and
substrate prepared immediately before use were added to each
well, and the color reaction was allowed to develop for 30
minutes at room temperature before stopping the reaction with
1 N HC1. Absorbance was read at 490 nm on a microplate reader
MR 600 (Dynatech Laboratories Inc.) within the subsequent
half hour. The extent of lysis of (32m negative cells was
calculated as follows:
% I3m cytotoxicity
(/32m + /32m) — (f32m + RPM!) — ((32m + RPM!)
(132m + Triton) — ((32m + RPMI) — (I32m + RPMI)
where ((32m + (32m) indicates cytotoxicity of the co-culture
well of 132m negative cells with f32m positive cells, and (f32m +
RPM!) and (j32m + RPMI) indicate background spontaneous
lysis which are subtracted to give true cytotoxicity. Similarly,
(/32mW + Triton) indicates total cytotoxicity of the f32m negative
fraction. The ratio, expressed as % true cytotoxicity, indicates
the extent of specific lysis of the J32m negative cells. This was
compared to the cytotoxic activity of NK cells against their
classical target K562, expressed similarly.
% K562 cytotoxicity =
(K562 + f32m) — (K562 + RPMI) — (/3,m + RPMI)
(K562 + Triton) — (K562 + RPMI) — (/32m + RPMI)
where (K562 + (32m) indicates cytotoxicity of K562 cells
incubated with f32m cells, and (K562 + RPM!) and (/32m +
RPM!) indicates spontaneous background lysis of these cells,
respectively. Spontaneous background lysis of the f32m and
132m cells did not exceed 15% of the mean maximum release.
Re-induction of (32in expression. Aliquots of purified fl2m
negative cells were left in culture for another 18 hours at 37°C.
Part of the j32m negative cells were stimulated with 500 pg/mi
rTNF-a or rIL- 1f3 (Genzyme, Boston, Massachusetts, USA)
and (32m and HLA expressions were assessed by cytofluorom-
etry as described previously.
Statistics. SAS statistical package was used in the statistical
analysis of the data. Comparisons between dialysis samples
were analyzed using ANOVA for balanced design studies, with
a posteriori testing for differences between specific groups
using the Bonferroni method, and the multiple comparison
adjustments on all main effect means. Comparison of baseline
patient values and controls, assessed in parallel, used (-test for
unpaired data. P < 0.05 was considered significant.
Results
Membrane markers on the separated PBMNC
Purity of the /32m negative population, negatively selected by
magnetic separation was assessed by anti-132m staining. On
average, 87 4% of the cells isolated by negative magnetic
separation were (32m negative cells. Recovery of f32m negative
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cells was >65% of the population estimated by staining of the
total population of PBMNC. Isolated 132m negative cells also
did not stain with W6/32, the antibody against the monomorphic
determinant of HLA. Other markers used to define this /32m
negative population demonstrated 70% CD2 positive, 35% CD3
positive, 10% CD4 positive and 2% CD8 positive. Staining for
CDS6, CD16 (B cells) and monocyte markers were comparable
to the unseparated PBMNC. Thus, there was no evidence of
specific clonal selection in these cells with reduced or absent
/32mIHLA expression on their surface.
Presence of f32m negative cells in PBMNC harvested from
hemodialysis patients
In all eight patients, the percentage of mononuclear cells
(PBMNC) that did not stain with the anti-f32m antibody, as
analyzed by cytofluorometry, was significantly higher at base-
line than normal controls. Thus, at the beginning of the study,
and before the use of new cuprophane membrane, the percent-
age of 32m negative cells was 7.0 2.1%, whereas in normal
controls, it was 2.9 0.7% (Fig. 2). There was a slight, but
non-significant (NS) increase after the first session using NCU
membranes (8.7 2.3%, P < 0.001 compared to normal
controls, but NS compared to baseline). The proportion of f32m
negative cells increased with duration of exposure to NCU
membranes and was 13.4 1.9% (P < 0.05 compared to
baseline) after the first week of NCU membrane use and
increased further to 19.6 4.1% after two weeks or six dialyses
with NCU membranes (P < 0.001 compared to baseline).
NK population in PBMNC in culture
CD56 (Leu-l9) expression was found in 17 5% of PBMNC
of dialysis patients at the beginning of the study. This was not
different from the values observed in normal controls of 21
3%. After culture in IL-2, CD56 expression increased to 27.7
7.9% of cells in culture in the dialysis patients, when sampled at
baseline, prior to the initiation of NCU dialysis (Fig. 3). During
the new cuprophane membrane period, the percentage of CD56
positive cells in IL-2 activated cultures increased from 47.5
16.8% after the first dialysis with NCU membranes (P <0.01
vs. baseline) up to 59.8 15.0% after the first week of NCU
dialysis (P < 0.05 vs. first CU dialysis), and remained stable at
59.2 12.0% after the second week of dialysis with NCU.
Conventional K562 cytotoxicity assay
K562 cytotoxicity by IL-2 activated PBMNC from hemodi-
alysis patients also varied according to the time of sampling:
K562 lysis by IL-2 activated PBMNC harvested at baseline (at
the beginning of the study) was 28.7 16.5%, not significantly
different from normals (31.8 14.4) [32—34] (Fig. 4); at the end
of the first CU dialysis, K562 cytolysis had doubled to 45.3
16.0% (P < 0.02 vs. baseline and normal controls). However,
when PBMNC were harvested after one week of cuprophane
dialysis, K562 cytolysis was significantly reduced to 19.5
7.2% (P < 0.03 vs. baseline and first CU dialysis). After the
second week of new cuprophane membrane, the cytotoxicity of
K562 was further reduced to 12.5 6.2% (P <0.001 compared
to baseline; Fig. 4). Thus, following the first exposure to
cuprophane membrane, there was an initial increase in the
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Fig. 2. Percent of f32m negative cells in normal controls (CTL), and in
dialysis patients participating in the study at baseline (BL) after 2
months of dialysis with a biocompatible membrane, and after the first
(1st C), one week (1-wk C) and 2 weeks (2-wk C) of dialysis with a new
cuprophane membrane.
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Fig. 3. Percent of NK cells (CD56 positive by flow cytometry) in
normal controls and hemodialysis patients during the study. Notation is
similar to Figure 2.
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Fig. 4. Percent cytotoxicity of NK cells against the classical target
(K562) cell line in normal controls and in hemodialysis patients during
the study, Notations are similar to those in Figure 2.
cytotoxicity of NK cells against the K562 cell line; subse-
quently, there was a steady decline in the functional ability of
the NK cells to respond to these K562 cells.
J32m cytotoxicity assay
When f32m positive PBMNC were placed in mixed culture
with their autologous /32m negative counterparts, specific cyto-
toxicity was somewhat higher than that seen for K562 (Fig. 5).
Thus, it was 32.5 12.4% of f32m negative PBMNC at baseline.
Nevertheless, f32m negative cell-mediated lysis doubled at the
end of the first week of NCU exposure to 60.6 2 1.5% (P <
0.01) and remained elevated at 61.3 23.7 (P < 0.001) at the
end of two weeks of NCU exposure. Thus, while cytolytic
activity of NK cells against K562 cells decreased during the
study period, the cytotoxicity against p2m negative/HLA neg-
ative cells increased during the same period of the study.
Normal controls did not have sufficient 132m negative cells to
perform a control experiment.
Re-induction of f32m expression by cytokines
When f3m negative cells were incubated with rTNFa or
rIL-1/3, the concentration of f32m negative cells decreased to 4.5
3% within two hours, while in unstimulated cells, the
concentration of f32m negative cells was still 39 14% after 24
hours [35]. Following re-expression of f32m (and HLA), cyto-
toxicity assays of these cells was 26.8 16% (N = 3), not
significantly different from values obtained at baseline.
Discussion
The results of this study confirm the emergence of a popula-
tion of cells with reduced f32m and HLA surface marker, as a
function of chronic exposure to new cuprophane membrane
[23]. The concomitant loss of both HLA and f32m can be
explained by the strong association of class I HLA antigens and
/32m on the surface of nucleated cells [35, 36]. The re-expression
of these markers following in vitro stimulation with IL-1/3 and
TNF-c suggests that the loss of the surface expression of these
molecules is not irreversible [10].
Sensitivity to NK cytolysis is related to low target cell
expression of major histocompatibility glycoproteins, as well as
f32m on the surface of these cells [6, 10, 12, 35, 37]. K562, an
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Figure 2.
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erythroleukemic cell line derived from a patient with chronic
myelogenous leukemia in blast phase, is frequently the target
used for standard assays of NK cytolysis, since it does not
express MHC antigens, but has unassociated f32m on its surface
[18, 33]. Cytolytic activity of NK cells against K562 target cells
typically occurs within hours of target cell exposure and with-
out prior deliberate immunization.
Using cytolytic activity of NK cells against K562, the results
of our study show a significant deterioration of NK function in
hemodialysis patients with initiation of dialysis with cu-
prophane membranes [38]. Thus, specific cytotoxicity de-
creased from 28.7 16.6% at baseline to 12.5 6.2% (P <
0.001) at the end of two weeks of dialysis with new cuprophane
membrane. Since baseline level of cytotoxicity measured
against K562 immediately before institution of NCU dialysis
(28.7 16.6%) is not significantly different from control values
of 31.8 14.4, it is likely that this observed decrease in
cytolytic function is not due to "uremic" factors, but is due to
the influence of the dialysis membrane on NK cell function
[39—42]. However, our studies did not address this issue spe-
cifically.
These results are in agreement with the studies by Raij and
Kay, who also found decreased activity of NK cells harvested
from normal volunteers and exposed to different dialysis mem-
branes in vitro [26, 27]. In those studies, the decrease in the
cytolytic activity of NK cells against K562 cells correlated with
the capacity of these membranes to activate complement (that
is, the decrease was greatest for cuprophane > cellulose acetate
> polycarbonate > controls). However, interestingly, the ad-
dition of purified C5a to non-adherent (monocyte-depleted)
large granular lymphocytes resuspended in serum-free media
did not result in alterations of NK activity against K562 [26].
The decrease in cytotoxicity of the K562 target cells with
chronic exposure to the cuprophane membrane in our study is
even more striking in view of the large increase in CD56 staining
of the PBMNC, suggesting an increase in the proportion of cells
with NK surface expression during the experimental phase of
the study. However, caution must be used in the identification
of NK cells with a specific surface antigen, particularly with the
Leu-7 (HNK-1) antigen and CD16, which have been found to be
non-specific for NK cells [41, 43, 44]. Although CD56, the
antigen used in the current study, is expressed by virtually all
human peripheral blood cells capable of non-MHC restricted
cytotoxicity [14], and its surface density increases when NK
cells are activated [45], a small fraction of PBMNC express
both CD56 and CD3, and do not appear to participate in
lymphokine activated killer cell activity [14]. CD56 is also
present on some IL-2 dependent cell lines that express CD8 or
CD4 [46]. Thus, in the absence of a unique marker for NK cells,
it is difficult to conclude that the increase in CD56 staining truly
represents an increase in NK cell number or that it correlates
with functional activity of NK cells.
The explanation for the difference in the extent of NK
cytotoxicity between the classical in vitro target K562 and the
132m negative cells isolated by immunomagnetic beads is not
clear. Several hypotheses can be advanced. It is possible that
these two phenomena are distinct and unrelated. It is also
possible that the sensitivity of autologous cells which have lost
their combined MHC glycoprotein as well as their f32m is
inherently greater than the sensitivity of K562 cell line where
132m expression is still intact [10, 12]. Alternately, a hypothesis
that may explain many of these findings in that these f32m
negative cells may have already undergone some degree of
sublethal damage in vivo prior to their isolation, and are
therefore more susceptible to further damage when in close
proximity to isolated NK cells in our in vitro assay. According
to this hypothesis, dialysis with cellulosic membranes leads to
the emergence of cells with reduced or absent /32m/MHC
glycoproteins on their surface and initially leads to an increase
in NK cell activity. This would result in an increase of the
number and activity of the NK cells. (Indeed, the initial high
specific cytotoxicity against the K562 cells seen after the first
cuprophane dialysis is in agreement with this hypothesis.)
However, the continued emergence of these f32m/HLA cells
during dialysis with CU leads to depletion of the preformed
granules and a weakened NK cell activity, as manifested by
decreased K562 cytolysis and the emergence of a larger number
of /32m/HLA negative cells in vivo. Further studies are needed
to confirm this hypothesis.
It is possible to speculate that these observations on NK cell
activity with recurrent dialysis with NCU have relevance to
several clinical observations of hemodialysis patients. The first
of these observations has been pointed out in several studies
which have documented an absolute lymphopenia in hemodial-
ysis patients (approximately 60% of normal controls) which is
progressive with years on dialysis [28, 34]. It is possible that
this lymphopenia is due to the ongoing autologous cytolysis of
emerging /32m/HLA negative cells [34, 41]. The second obser-
vation is the depressed immune function of hemodialysis pa-
tients, manifested by an increased incidence of viral infections,
malignancy and a reduced mixed lymphocyte reaction in hemo-
dialysis patients [47—51]. Since the primary function of NK cells
is the defense against virally infected and malignant cells
(usually not bearing MHC glycoproteins), decreased cytolytic
activity of NK cells, as seen in this study, may be part of the
explanation for this clinical observation. Finally, NK cytotox-
icity of autologous lymphocytes may participate in the clonal
depletion of specific T-cells, previously sensitized to specific
antigens (for example, viral antigens administered as vaccines
or HLA antibodies) and may thus be a partial explanation for
the decreased immunological response to vaccine and possibly
in the development of "historically positive, current negative"
HLA antibodies observed in some chronic dialysis transplant
candidates. Such speculation can be checked with on-going
studies of outcome with different dialysis membranes.
In summary, our results indicate that in chronic dialysis
patients, NK cell activity is weakened by the chronic use of
complement activating membranes. In addition, these studies
confirm the emergence of a subpopulation of 132m/HLA nega-
tive cells, in agreement with the findings of weakened NK cell
activity. Finally, these findings may be relevant to several
clinical observations in hemodialysis patients.
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